Immunohistochemical characterisation of breast cancer: Towards a new clasification?;Características inmunohistoquímicas del cáncer de mama: ¿Hacia una nueva clasificación?

Cirugia Espanola

Volumn 84, Issue 3, 2008, Pages 138-145

  Piñero Madrona, Antonio ^a   Polo García, Luis ^a   Alonso Romero, José Luis ^a   Salinas Ramos, Juan ^a   Canteras Jordana, Manuel ^b   Sola Pérez, Joaquín ^a   Galindo Fernández, Pedro J ^a   Illana Moreno, Julián ^a   Bermejo López, Juan ^a   Navarrete Montoya, Agustín ^a   Parrilla Paricio, Pascual ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Breast cancer; Her2neu; Hormone receptors; Immunohistochemistry; Oestrogen receptors; Progesterone receptors

Indexed keywords

EID: 51849112805     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(08)72155-9     Document Type: Article

References (35)

1. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37-47.
2. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254-61.
3. Ciocca DR, Gago FE, Fanelli MA, Calderwood SA. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2-neu: clinical implications. J Steroid Biochem Mol Biol. 2006;102:32-40.
4. Railo M, Lundin J, Haglund C, Von Smitten K, Nordling S. ki-67, p53, ER receptors, ploidy and S-phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol. 2006;28:45-51.
5. Sorlie T, Perou CM, Tibshirani RT, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74.
6. Glinsky GV, Higashiyama T, Glinskii AB. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clin Cancer Res. 2004;10:2272-83.
7. Sorlie T. Molecular portraits of breast cancer: tumor subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-75.
8. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-60.
9. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127-42.
10. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-81.
11. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AHS, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modern Pathology. 2005;18:26-35.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
13. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kaha HK, Sawka CA, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
14. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
15. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MCU, Akslen LA, et al. Using of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134-45.
16. a ed. New York: Wiley-Lliss; 2002.
17. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jefrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52.
18. Sorlie T, Tibshirani R, Parker J, Parker J, Hastie T, Marron JS, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-23.
19. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expresión profilesof human breast cancer progresión. Proc Natl Acad Sci U S A. 2003;100;5974-9.
20. Kusinska R, Potemski P, Jesionek-Kupnicka D, Kordek R. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma: relation with grade, stage, estrogen receptor and HER-2. Pol J Pathol. 2005;56:107-10.
21. a ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 603-17.
22. a ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 619-52.
23. Carey LA, Perou CM, Dressler LG, Livasy CA, Dressler LG, Cowan D, et al. Race and the poor prognosis basal-like breast cancer (BBC) phenotype in the population-based Carolina Breast Cancer Study. J Clin Oncol. 2004 Suppl; abstract 9510.
24. Kim Mj, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormonoreceptor and Her2neu-overexpression phenotypes. Hum Pathol. 2006;37:1217-26.
25. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212-20.
26. Lanari C, Molinolo AA. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res. 2002;4:240-3.
27. Connely OM, Jericevic BM, Lydon JP. Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2003;8:205-14.
28. Aupperlee M, Kariagina A, Osuch J, Haslam SZ. Progestins and breast cancer. Breast Dis. 2005;24:37-57.
29. Martin M. Molecular biology of breast cancer. Clin Transl Oncol. 2006;8:7-14.
30. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-9.
31. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721-35.
32. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterona receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006;106:2576-82.
33. Yamashita H, Ando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 2006;13:74-83.
34. Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006;12:159-68.
35. Liedtke C, Mazouni C, Hess KR, Andre F, Tordani A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;26:1275-81.